Celsion Corporation Announces Presentation Of Results From Independent NIH Analysis Of ThermoDox® Plus Optimized RFA For The Treatment Of Primary Liver Cancer At The 2016 RSNA Annual Meeting

NIH Analysis of Data from Celsion's HEAT Study Reaffirms Correlation Between Increased RFA Burn Time per Tumor Volume and Significant Improvements in Overall Survival

Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit for Patients Treated with ThermoDox® Plus Optimized RFA Compared with Optimized RFA Alone

LAWRENCEVILLE, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced the presentation of results from an independent retrospective analysis conducted by the National Institutes of Health (NIH) on the intent-to-treat population of the Company's HEAT Study, a 701-patient study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The findings of the NIH study were presented during The Interventional Oncology Series: Hepatocellular Carcinoma and Cholangiocarcinoma at the 102 nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) on Monday, November 28, 2016 from 1:00 pm to 6:00 pm CT and was moderated by Professor Riccardo Lencioni, lead European Investigator on Celsion's HEAT Study.  Celsion is currently studying the use of RFA as a heat source both for tumor ablation and to activate ThermoDox® as a means of affecting the area surrounding the tumor, where later recurrence most often takes place.

The NIH analysis was conducted under the direction of Dr. Bradford Wood, MD, Director, NIH Center for Interventional Oncology and Chief, NIH Clinical Center Interventional Radiology. The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome, concluded that increased burn time per tumor volume significantly improved overall survival (OS) in patients with solitary lesions treated with RFA + ThermoDox® compared to patients treated with RFA alone.  More specifically, the analysis showed that a one unit increase in RFA duration per tumor volume improved OS by 20% in patients treated with optimized RFA + ThermoDox® compared to RFA alone.

If you liked this article you might like

Food for Thought: Could Carefree Bulls Soon Utter 'What Were We Thinking?'

These 5 Stocks Under $10 Could Explode Up Soon

Insider Trading Alert - BDX, CLSN And ACTG Traded By Insiders

One Reason Celsion (CLSN) Stock Is Soaring